439094-96-9

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylic acid is used as a pharmaceutical compound for its potential to interact with specific targets in the body. Its unique structure allows it to be a candidate for the development of new drugs with targeted therapeutic effects.
Used in Biological Research:
In the field of biological research, 2,4-Bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylic acid is used as a research tool to study the interactions between chemical compounds and biological systems. Its unique structure provides insights into the mechanisms of action and potential applications in various biological processes.
Used in Drug Development:
2,4-Bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylic acid is used in drug development as a starting point for the synthesis of new compounds with potential therapeutic effects. Its unique structure and functional groups can be modified to create derivatives with improved pharmacological properties and selectivity for specific targets.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2,4-Bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylic acid is used as a building block for the creation of more complex molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Overall, the unique structure and potential applications of 2,4-Bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylic acid make it a valuable compound for researchers and pharmaceutical companies to explore and develop for various purposes in different industries.

Upstream product

• 1522-22-1 1,1,1,5,5,5-hexafluoroacetylacetone 
• 141-86-6 2.6-diaminopyridine 
• 1420681-37-3 ethyl 2,4-bis(trifluoromethyl)imidazo[1,2-a][1,8]naphthyridine-8-carboxylate 
• 51420-72-5 7-amino-2,4-bis(trifluoromethyl)-1,8-naphthyridine 

Relevant academic research and scientific papers

Development of an anti-hepatitis B virus (HBV) agent through the structure-activity relationship of the interferon-like small compound CDM-3008

Hepatitis B, a viral infectious disease caused by hepatitis B virus (HBV), is a life-threatening disease that leads liver cirrhosis and liver cancer. Because the current treatments for HBV, such as an interferon (IFN) formulation or nucleoside/nucleotide

Discovery of Imidazo[1,2-α][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor

RO8191 represents a newly discovered small-molecule IFN-like agent that displays potent anti-HCV activity. With it as lead, a series of compounds bearing an imidazo[1,2-α][1,8]naphthyridine core and an amide bond-linked side chain were designed and synthesized. These compounds were evaluated on HCV cell culture system (HCVcc-hRluc-JFH1), and some of them exhibited remarkable anti-HCV activity (EC50 = 0.017-0.159 μM) and low toxicity (CC50 > 25 μM). Moreover, it was revealed that these newly identified anti-HCV agents exert their antiviral effect through a distinct mechanism of action from that of RO8191 by targeting the viral entry process. Thus, our study provides a starting point for the development of potential HCV entry inhibitor.

IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS

The present disclosure relates to agonists of interferon alpha and beta receptor subunit 2 (IFNAR2) for use in the treatment or prevention of viral disease, particularly COVID-19. In particular embodiments, COVID-19 is associated with pneumonia or acute respiratory distress syndrome (ARDS). In other aspects, the subject being treated is undergoing extra-corporeal membrane oxygenation, mechanical ventilation, non-invasive ventilation, receiving oxygen therapy or receiving antiviral or steroid treatment.

COMPOUNDS AND METHODS FOR ENHANCING INNATE IMMUNE RESPONSES

Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.